Overview
LIMN market data
Price History
LIMN price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$0.43 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.72 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $0.10 – $9.38 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · source Twelve Data /statistics · market cap $8.2.
Company news
Dow Gains Over 250 Points; US Jobs Rise By 57,000 In JuneBenzinga · Jul 2, 2026, 1:55 PM
Liminatus Pharma Amends Proposed $320M Merger Deal With InnocsAI As Closing Now Anticipated Before Shareholder Approval On July 2Benzinga · Jun 30, 2026, 8:35 PM
Deal Dispatch: IMAX Mulls Potential Sale, Shein Buys Everlane, West Marine BankruptcyBenzinga · May 22, 2026, 6:40 PM
Why Estee Lauder Shares Are Trading Higher By 12%; Here Are 20 Stocks Moving PremarketBenzinga · May 22, 2026, 1:05 PM
Crude Oil Moves Higher; Walmart Shares Fall After Q1 ResultsBenzinga · May 21, 2026, 4:10 PM
US Stocks Lower; Nvidia Posts Upbeat EarningsBenzinga · May 21, 2026, 2:10 PM
Liminatus Pharma Announces Proposed Merger with InnocsAI to Expand Oncology Cell Therapy PipelineBenzinga · May 21, 2026, 1:15 PM
Liminatus Pharma Entered Definitive Agreement To Acquire InnocsAI On May 17 In $320M All-Stock TransactionBenzinga · May 21, 2026, 12:15 PM
Liminatus Pharma Enters Merger Agreement With InnocsAI On May 17, 2026; InnocsAI Members To Receive 1.6B Shares At $0.20 Per Share And 20% Contingent Value RightsBenzinga · May 20, 2026, 9:20 PM